Head to Head Review: Accelerate Diagnostics (AXDX) versus its Peers
Accelerate Diagnostics (NASDAQ: AXDX) is one of 82 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its competitors? We will compare Accelerate Diagnostics to similar businesses based off the strength of its analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.
Risk and Volatility
Accelerate Diagnostics has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Comparatively, Accelerate Diagnostics’ competitors have a beta of 0.89, suggesting that their average stock price is 11% less volatile than the S&P 500.
This is a summary of recent ratings and recommmendations for Accelerate Diagnostics and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Accelerate Diagnostics Competitors||415||2177||3381||122||2.53|
Accelerate Diagnostics presently has a consensus price target of $33.00, suggesting a potential upside of 42.24%. All “Advanced Medical Equipment & Technology” companies have a potential downside of 21.29%. Given Accelerate Diagnostics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Accelerate Diagnostics is more favorable than its competitors.
Valuation & Earnings
This table compares Accelerate Diagnostics and its competitors gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Accelerate Diagnostics||$1.29 million||-$61.92 million||-18.86|
|Accelerate Diagnostics Competitors||$2.01 billion||$429.46 million||-57.72|
Accelerate Diagnostics’ competitors have higher revenue and earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently the more expensive than other companies in its industry.
This table compares Accelerate Diagnostics and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Accelerate Diagnostics Competitors||-332.42%||-34.27%||-13.19%|
Insider and Institutional Ownership
44.4% of Accelerate Diagnostics shares are owned by institutional investors. Comparatively, 53.1% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 51.4% of Accelerate Diagnostics shares are owned by company insiders. Comparatively, 16.8% of shares of all “Advanced Medical Equipment & Technology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Accelerate Diagnostics competitors beat Accelerate Diagnostics on 7 of the 12 factors compared.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.
Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.